Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer

References

• Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol 2012;27:1423–31.
   PubMed Web of Science ®Google Scholar
• Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449–60.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004;23:29–39.
   PubMed Web of Science ®Google Scholar
• Naghibalhossaini F, Zamani M, Mokarram P, Khalili I, Rasi M, Mostafavi-Pour Z. Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Mol Biol Rep 2012;39:6171–8.
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183–8.
   PubMed Web of Science ®Google Scholar
• Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004;31:12–21.
   PubMed Web of Science ®Google Scholar
• Dimberg J, Samuelsson A, Hugander A, Söderkvist P. Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer. Anticancer Res 1998;18:3283–7.
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Morrow RD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362–6.
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075–81.
   PubMed Web of Science ®Google Scholar
• Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S. Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem 2003;253:141–9.
   PubMed Web of Science ®Google Scholar
• Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: Classification and characterization. Biochim Biophys Acta 2000;1488:1–19.
   PubMed Web of Science ®Google Scholar
• Cummings BS. Phospholipase A2 as target for anti-cancer drugs. Biochem Pharmacol 2007;74:949–59.
   PubMed Web of Science ®Google Scholar
• Smith WL, Lagenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001;107:1491–5.
   PubMed Web of Science ®Google Scholar
• Österström A, Dimberg J, Fransen K, Söderkvist P. Expression of cytosolic and group X secretory phospholipase A2 genes in human colorectal adenocarcinomas. Cancer Lett 2002;1982:175–82.
   Web of Science ®Google Scholar
• Panel V, Boelle PY, Ayala-Sanmartin J, Jouniaux AM, Hamelin R, Masliah J, et al. Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett 2006;243:255–63.
   PubMed Web of Science ®Google Scholar
• Yoo YS, Lim SC, Kim KJ. Prognostic significance of cytosolic phospholipase A2 expression in patients with colorectal cancer. J Korean Surg Soc 2011;80:397–403.
   PubMed Web of Science ®Google Scholar
• Bumeida A, Bendardaf R, Hilska M, Laine J, Collan Y, Laato M, et al. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Ann Oncol 2009;20:1230–5.
   PubMed Web of Science ®Google Scholar
• Murakami M, Masuda S, Kudo I. Arachidonate release and prostaglandin production by group IVC phospholipase A2 (cytosolic phospholipase A2γ). J Biochem 2003;372:695–702.
   Web of Science ®Google Scholar
• Asai K, Hirabayashi T, Houjou T, Uozumit N, Taguchi R, Shimizu T. Human group IVC phospholipase A2 (cPLA2γ). Roles in the membrane remodeling and activation induced by oxidative stress. J Biol Chem 2003;278:8809–14.
   PubMed Web of Science ®Google Scholar
• Yamashita A, Tanaka K, Kamata R, Kumazawa T, Suzuki N, Koga H, et al. Subcellular localization and lysophospholipase/transacylation activities of human group IVC phospholipase A2 (cPLA2 gamma). Biochim Biophys Acta 2009;1791:1011–22.
   PubMed Web of Science ®Google Scholar
• Tian G, Wang X, Zhang F, Geng H, Hou W, Chen L, et al. Downregulation of cPLA2γ expression inhibits EGF-induced chemotaxis of human breast cancer cells through Akt pathway. Biochem Biophys Res Commun 2011;409:506–12.
   PubMed Web of Science ®Google Scholar
• Goel A, Boland CR. Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol 2010;26:47–52.
   PubMed Web of Science ®Google Scholar
• Mammano E, Belluco C, Bonafe M, Olivieri F, Mugianesi E, Barbi C, et al. Association of p53 polymorphisms and colorectal cancer: Modulation of risk and progression. Eur J Surg Oncol 2009;35:415–19.
   PubMed Web of Science ®Google Scholar
• Theodoropoulos G, Papaconstantinou I, Felekouras E, Niketeas N, Karakitsos P, Panoussopoulos D, et al. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 2006;12:5037–43.
   PubMed Web of Science ®Google Scholar
• Tao R, Yu Y, Zhang X, Guo Y, Shi J, Zhang X, et al. Cytosolic PLA2 genes possibly contribute to the etiology of schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2005;137B:56–8.
   PubMed Web of Science ®Google Scholar
• Yu Y, Tao R, Shi J, Zhang X, Kou C, Guo Y, et al. A genetic study of two calcium-independent cytosolic PLA2 genes in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2005;73:351–4.
   PubMed Web of Science ®Google Scholar
• Gertler R, Rosenberg R, Schuster T, Friess H. Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy. Eur J Cancer 2009;45:2992–9.
   PubMed Web of Science ®Google Scholar
• Sobrero A. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol 2006;7:515–16.
   PubMed Web of Science ®Google Scholar
• O’Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011;29:3381–8.
   PubMed Web of Science ®Google Scholar
• Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: How much evidence is enough? Ann Oncol 2003;14:1026–38.
   PubMed Web of Science ®Google Scholar
• Böckelman C, Engelman BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncol 2015:54:5–16.
   PubMed Web of Science ®Google Scholar
• Glimelius B. Adjuvant chemotherapy for patients with rectal cancer – will the controversy be resolved? Acta Oncol 2015:54:433–6.
   PubMed Web of Science ®Google Scholar
• Akiyoshi T, Kobunai T, Watanabe T. Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today 2012;42:1037–45.
   PubMed Web of Science ®Google Scholar